Navigation Links
AstraZeneca Sued Over Alleged Nexium Injuries, According to The Gibson Law Firm

HOUSTON, April 19, 2011 /PRNewswire/ -- An Ohio woman suffered bone deterioration and broken bones because of hidden risks with pharmaceutical giant AstraZeneca's acid reflux drug Nexium, The Gibson Law Firm alleges in a lawsuit filed today in Texas federal court.

Filed in the U.S. District Court in Houston, the lawsuit alleges 58-year-old Ginny Begin, of Toledo, Ohio, suffered serious bone deterioration after taking Nexium on a daily basis between 2003 and early 2011.

In March, the FDA issued a safety alert stating use of prescription "PPI's," including Nexium, results in an increased risk of fractures. PPI's are prescription-strength proton pump inhibitors. In May 2010, the FDA mandated manufacturers of PPI's such as Nexium to include safety information and warnings about the increased risk of osteoporosis and fractures associated with PPIs.

The lawsuit alleges, "[A]s early as 2006, studies found PPI's, by reducing hydrochloric acid in the stomach, interfere with the body's ability to absorb calcium, thus speeding up bone loss and leading to an increased number of fractures. In total, six studies have found the risk of fracture significantly increased for those patients over 50 years of age who took a prescription-strength PPI, like Nexium, or who took any PPI regularly for more than one year. Specifically, use of PPI's increases the risk of fractures in women up to 34 percent."

According to the complaint, Begin snapped a leg bone (left fibula) in July 2005 while walking. In June 2007, the same bone in Begin's leg and three bones in her ankle broke as she walked down stairs.

Jason A. Gibson of The Gibson Law Firm in Houston represents Begin. He stated, "Despite knowing Nexium causes bones to severely deteriorate and break, AstraZeneca marketed and sold Nexium without warning consumers of the significant risks of bone deterioration and fractures. Ms. Begin continues to suffer severe pain from leg and ankle injuries that never fully healed. Our investigation of national impact on consumers who took Nexium continues. This appears to be the first known lawsuit filed against AstraZeneca arising from bone fractures caused by Nexium."

The lawsuit accuses AstraZeneca, L.P. and AstraZeneca Pharmaceuticals, L.P. of negligence, negligent misrepresentation and product defects, and seeks exemplary damages.

The case is "Ginny Begin v. AstraZeneca, L.P.," Civil Action No. 4:11-CV-01489 in the U.S. District Court for the Southern District of Texas, Houston Division.

SOURCE The Gibson Law Firm
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
2. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
3. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
4. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
5. AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication
6. Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
7. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
8. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
9. AstraZeneca Submits sNDA for NEXIUM(R) I.V. for Peptic Ulcer Bleed Indication
10. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
11. AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six
Post Your Comments:
(Date:11/26/2015)... 26, 2015 ... of the  "2016 Future Horizons and ... Drug Monitoring (TDM) Market: Supplier Shares, ... Opportunities"  report to their offering.  ... the addition of the  "2016 Future ...
(Date:11/26/2015)... 26, 2015 ... of the  "2016 Future Horizons and ... Surface Marker Testing Market: Supplier Shares, ... their offering.  --> ... the  "2016 Future Horizons and Growth ...
(Date:11/25/2015)... Nov. 25, 2015  Linden Care, LLC, a retail ... outcomes for patients suffering from chronic pain, said today ... Temporary Restraining Order (TRO) enjoining Express Scripts from unilaterally ... --> --> The ... its legal options. --> ...
Breaking Medicine Technology:
(Date:11/26/2015)... San Antonio, TX (PRWEB) , ... November 26, 2015 , ... ... accomplishment! On November 19, 2015, our surgeons performed their 6,000th free flap breast ... Ledoux , “We wake up every day excited to rebuild lives and it’s an ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... than those found on mammography, according to a study published online in the ... not seen on mammography may necessitate a change in treatment. , Breast MRI ...
(Date:11/25/2015)... ... November 25, 2015 , ... TyloHelo Inc , ... accessories. , Sauna accessories help improve the bather experience in the sauna, and ... styles for the purist looking for simplicity in design to accessories that encourage ...
(Date:11/25/2015)... , ... November 25, 2015 , ... According to an ... robot is being more and more widely heralded as a breakthrough for performing hernia ... method has over traditional laparoscopic surgery is that it can greatly reduce the pain ...
(Date:11/25/2015)... ... , ... The McHenry County law firm of Botto Gilbert Lancaster, PC ... J. Botto and Alex C. Wimmer. Attorneys Botto and Wimmer represented the claimant David ... 130884WC. , According to court documents, Adcock testified that on May 10, 2010 he ...
Breaking Medicine News(10 mins):